Chemenon Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.60 M
as on 16-11-2024
- Company Age 54 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Profit 55.32%
(FY 2023)
- Ebitda 55.32%
(FY 2023)
- Net Worth -2.55%
(FY 2023)
- Total Assets -1.55%
(FY 2023)
About Chemenon Pharma
The Company is engaged in the Real Estate And Construction Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.60 M, as per Ministry of Corporate Affairs (MCA) records.
Ruchita Gala, Monil Gala, Mehul Gala, and One other member serve as directors at the Company.
- CIN/LLPIN
U70100MH1970PTC014852
- Company No.
014852
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Oct 1970
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Chemenon Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ruchita Gala  | Director | 16-Jul-2018 | Current |
| Monil Gala | Director | 26-Aug-2021 | Current |
| Mehul Gala | Director | 26-Aug-2021 | Current |
| Mahendra Gala | Director | 18-Jan-1989 | Current |
Financial Performance of Chemenon Pharma.
Chemenon Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 55.32% increase in profit. The company's net worth dipped by a decrease of 2.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chemenon Pharma?
In 2023, Chemenon Pharma had a promoter holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Streamline Finance And Investment Private LimitedActive 41 years 1 day
Monil Gala, Mehul Gala and 1 more are mutual person
- Kleem Investments And Trading Pvt LtdActive 32 years 9 months
Monil Gala, Mehul Gala and 1 more are mutual person
- Blue Diamond Spaces Private LimitedActive 29 days
Monil Gala, Mehul Gala and 1 more are mutual person
- Steel Plant Private LimitedActive 65 years 9 months
Monil Gala, Mehul Gala and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Chemenon Pharma?
Unlock and access historical data on people associated with Chemenon Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chemenon Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chemenon Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
